Safety and Efficacy of Yttrium-90 Ibritumomab Tiuxetan in Older Patients With Non-Hodgkin's Lymphoma
- 1 October 2007
- journal article
- research article
- Published by SAGE Publications in Cancer Biotherapy and Radiopharmaceuticals
- Vol. 22 (5) , 684-691
Abstract
Objective: Treatment-related complications are more common in older patients with non-Hodgkin's lymphoma (NHL), often leading to chemotherapy modifications that can compromise efficacy. We analyzed data from clinical trials of yttrium-90-ibritumomab tiuxetan (Zevalin®; Biogen Idec, Cambridge, MA) to determine its safety and efficacy in older patients with NHL. Design and Methods: Data on safety and efficacy from four clinical trials of 90Y-ibritumomab tiuxetan in 211 patients with NHL were pooled and analyzed by ages of Results: Patients ≥70 years had a similar incidence of grade 3 or 4 neutropenia (68% vs. 66%), thrombocytopenia (68% vs. 70%), anemia (8% vs. 22%), and nonhematologic adverse events (23% vs. 19%) as that observed in patients Conclusions: Yttrium-90-ibritumomab tiuxetan produces high rates of clinical response (up to 80%) and durable remissions in patients with NHL, and can be given at standard doses in older patients. The favorable safety profile of the regimen makes it an effective treatment for older patients, who may not otherwise tolerate the adverse events associated with chemotherapy.Keywords
This publication has 26 references indexed in Scilit:
- Cancer Statistics, 2007CA: A Cancer Journal for Clinicians, 2007
- Subsequent therapy can be administered after tositumomab and iodine I-131 tositumomab for non-Hodgkin lymphomaCancer, 2006
- Treatment with yttrium 90 ibritumomab tiuxetan at early relapse is safe and effective in patients with previously treated B-cell non-Hodgkin's lymphomaLeukemia & Lymphoma, 2006
- Abbreviated Chemotherapy With Fludarabine Followed by Tositumomab and Iodine I 131 Tositumomab for Untreated Follicular LymphomaJournal of Clinical Oncology, 2005
- 131I-Tositumomab Therapy as Initial Treatment for Follicular LymphomaNew England Journal of Medicine, 2005
- Rituximab in Combination With Fludarabine Chemotherapy in Low-Grade or Follicular LymphomaJournal of Clinical Oncology, 2005
- Follicular Lymphoma International Prognostic IndexBlood, 2004
- Follow-Up Results of a Phase II Study of Ibritumomab Tiuxetan Radioimmunotherapy in Patients with Relapsed or Refractory Low-Grade, Follicular, or Transformed B-Cell Non-Hodgkin's Lymphoma and Mild ThrombocytopeniaCancer Biotherapy and Radiopharmaceuticals, 2004
- Durable responses after ibritumomab tiuxetan radioimmunotherapy for CD20+ B-cell lymphoma: long-term follow-up of a phase 1/2 studyBlood, 2004
- Subsequent Chemotherapy Regimens Are Well Tolerated After Radioimmunotherapy With Yttrium-90 Ibritumomab Tiuxetan for Non-Hodgkin’s LymphomaJournal of Clinical Oncology, 2002